Study #2022-0952
A phase 1, open-label, safety, tolerability, and efficacy study of NC525 in subjects with advanced myeloid neoplasms
MD Anderson Study Status
Not Accepting
Treatment Agent
NC525
Description
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Chronic Myelomonocytic Leukemia, Relapsed or Refractory Myelodysplastic Syndrome
Study phase:
Phase I
Physician name:
Nicholas Short
Department:
Leukemia
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.